CCT196969 50 mg | 99.65%
TargetMol
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
More Information Supplier PageCCT196969
Search Results
CCT196969 2 mg | 99.65%
TargetMol
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
More Information Supplier PageCCT196969
CCT196969 25 mg | 99.65%
TargetMol
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
More Information Supplier PageCCT196969
Vardenafil hydrochloride trihydrate 50 mg | Purity Not Available
TargetMol
Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
More Information Supplier PageVardenafil hydrochloride trihydrate
Vardenafil hydrochloride trihydrate 25 mg | Purity Not Available
TargetMol
Vardenafil HCl Trihydrate is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
More Information Supplier PageVardenafil hydrochloride trihydrate
PKM2-IN-1 100 mg | 99.90%
TargetMol
PKM2-IN-1 (compound 3k) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.
More Information Supplier PagePKM2-IN-1
PKM2-IN-1 200 mg | 99.90%
TargetMol
PKM2-IN-1 (compound 3k) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.
More Information Supplier PagePKM2-IN-1
PKM2-IN-1 50 mg | 99.90%
TargetMol
PKM2-IN-1 (compound 3k) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.
More Information Supplier PagePKM2-IN-1
ML335 5 mg | 99.42%
TargetMol
ML335
ML335 50 mg | 99.42%
TargetMol
ML335